Reinventing pulmonary care medically improves early diagnosis and interdisciplinary management for complex patients with COPD and co-morbidities.

CEO Barry Quart outlined the company’s focus on rademikibart, an IL-4 receptor alpha monoclonal antibody he described as a ...

Researchers have found in a new study that the hemoglobin, albumin, lymphocyte, and platelet score serves as an independent predictor of 30-day readmission in patients with acute exacerbation ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field ...

The global pulmonary drug delivery technology market is projected to grow at a CAGR of approximately 5% over the next five years. This growth is driven by the rising prevalence of respiratory diseases ...

Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...

A valved holding chamber with high drug delivery performance may reduce wheezing severity and hospitalizations more ...

Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...

When you or someone you care for suddenly doesn’t feel well, and needs urgent medical advice, the first question is often, ...

The risk for clinically relevant bleeding is significantly lower with apixaban than with rivaroxaban among patients with acute venous thromboembolism, according to a study published in the March 12/19 ...

Overall, 5.7 percent of participants with MCI had one-year risk for any indication for anticoagulant and thrombolytic drugs ...

In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.